Medpace Holdings, Inc. (NASDAQ:MEDP) Stake Trimmed by Wealth Alliance

Wealth Alliance lowered its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 9.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 865 shares of the company’s stock after selling 91 shares during the quarter. Wealth Alliance’s holdings in Medpace were worth $287,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Iron Triangle Partners LP acquired a new stake in Medpace during the 3rd quarter worth about $64,371,000. Wellington Management Group LLP boosted its position in Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after acquiring an additional 109,886 shares during the period. DF Dent & Co. Inc. boosted its position in Medpace by 189.9% during the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company’s stock worth $53,841,000 after acquiring an additional 105,659 shares during the period. Caisse DE Depot ET Placement DU Quebec acquired a new stake in Medpace during the 3rd quarter worth about $23,321,000. Finally, International Assets Investment Management LLC boosted its position in Medpace by 38,432.9% during the 3rd quarter. International Assets Investment Management LLC now owns 57,414 shares of the company’s stock worth $19,165,000 after acquiring an additional 57,265 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of Medpace stock opened at $340.78 on Friday. The firm has a market cap of $10.38 billion, a price-to-earnings ratio of 26.98, a P/E/G ratio of 3.80 and a beta of 1.36. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77. The stock has a 50-day simple moving average of $343.23 and a 200-day simple moving average of $347.46.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Robert W. Baird raised their price objective on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Medpace presently has an average rating of “Hold” and an average price target of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.